{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:30Z","timestamp":1794047430774,"version":"4.8.0"},"reference-count":40,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Debates on the role and timing of allogeneic hemtopoietic stem cell transplantation (HSCT) in acute myelogenous leukemia (AML) have persisted for decades. Time to transplant introduces an immortal time and current treatment algorithm mainly relies on the European LeukemiaNet disease risk classification. Previous studies are also limited to age groups, remission status and other ill-defined parameters. We studied all patients at diagnosis irrespective of age and comorbidities to estimate the cumulative incidence and potential benefit or disadvantage of HSCT in a single center. As a time-dependent covariate, HSCT improved overall survival in intermediate- and poor-risk patients (hazard ratio =0.51; P=0.004). In goodrisk patients only eight were transplanted in first complete remission. Overall, the 4-year cumulative incidence of HSCT was only 21.9% but was higher (52.1%) for patients in the first age quartile (16-57 years old) and 26.4% in older patients (57-70 years old) (P&lt;0.001). It was negligible in patients older than 70 years reflecting our own transplant policy but also barriers to transplantation (comorbidities and remission status). However, HSCT patients need to survive, be considered eligible both by the referring and the HSCT physicians and have a suitable donor to get transplantation. We, thus, comprehensively analyzed the complete decision-making and outcome of all our AML patients from diagnosis to last followup to decipher how patient allocation and therapy inform the value of HSCT. The role of HSCT in AML is shifting with broad access to different donors including haploidentical ones. Thus, it may (or may not) lead to increased numbers of allogeneic HSCT in AML in adults.<\/jats:p>","DOI":"10.3324\/haematol.2023.282729","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:25:37Z","timestamp":1679545537000},"page":"2369-2379","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience"],"prefix":"10.3324","volume":"108","author":[{"given":"Gerard","family":"Socie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Edouard","family":"Debureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lenglin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore Sicre","family":"De Fontbrune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"S\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali\u00e9nor","family":"Xhaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathana","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Couprie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Dhedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Dragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lemaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Clappier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Soulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis Peffault","family":"De Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"51330","doi-asserted-by":"crossref","unstructured":"Estey E, D\u00f6hner H. Acute myeloid leukaemia. Lancet. 2006; 368(9550):1894-1907.","DOI":"10.1016\/S0140-6736(06)69780-8"},{"key":"51331","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016; 127(1):62-70.","DOI":"10.1182\/blood-2015-07-604546"},{"key":"51332","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10):579-590.","DOI":"10.1038\/nrclinonc.2012.150"},{"key":"51333","doi-asserted-by":"crossref","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018; 392(10147):593-606.","DOI":"10.1016\/S0140-6736(18)31041-9"},{"key":"51334","doi-asserted-by":"crossref","unstructured":"Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373(9674):1550-1561.","DOI":"10.1016\/S0140-6736(09)60237-3"},{"key":"51335","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015; 373(12):1136-1152.","DOI":"10.1056\/NEJMra1406184"},{"key":"51336","doi-asserted-by":"crossref","unstructured":"Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission?. Leukemia. 2014; 28(10):1949-1952.","DOI":"10.1038\/leu.2014.129"},{"key":"51337","doi-asserted-by":"crossref","unstructured":"Gale RP, Lazarus HM. Correcting 2 more myths regarding transplants for AML in second remission. Blood. 2014; 123(5):794.","DOI":"10.1182\/blood-2013-12-541508"},{"key":"51338","doi-asserted-by":"crossref","unstructured":"Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukaemia?. Leukemia. 2017; 31(6):1255-1258.","DOI":"10.1038\/leu.2017.56"},{"key":"51339","doi-asserted-by":"crossref","unstructured":"Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013; 121(7):1077-1082.","DOI":"10.1182\/blood-2012-08-234492"},{"key":"51340","doi-asserted-by":"crossref","unstructured":"Zittoun RA, Mandelli F, Willemze R. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332(4):217-223.","DOI":"10.1056\/NEJM199501263320403"},{"key":"51341","doi-asserted-by":"crossref","unstructured":"Burnett AK, Goldstone A, Hills RK. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013; 31(10):1293-1301.","DOI":"10.1200\/JCO.2011.40.5977"},{"key":"51342","doi-asserted-by":"crossref","unstructured":"Burnett AK, Hills RK, Russell N. Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?. Br J Haematol. 2020; 188(1):86-100.","DOI":"10.1111\/bjh.16359"},{"key":"51343","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"51344","doi-asserted-by":"crossref","unstructured":"Del Galy AS, Marouf A, Raffoux E. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 2021; 35(1):225-228.","DOI":"10.1038\/s41375-020-1004-9"},{"key":"51345","doi-asserted-by":"crossref","unstructured":"Russell NH, Hills RK, Thomas A. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. 2022; 107(7):1518-1527.","DOI":"10.3324\/haematol.2021.279010"},{"key":"51346","doi-asserted-by":"crossref","unstructured":"Ustun C, Le-Rademacher J, Wang H-L. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019; 33(11):2599-2609.","DOI":"10.1038\/s41375-019-0477-x"},{"key":"51347","doi-asserted-by":"crossref","unstructured":"Appelbaum FR. Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2017; 30(4):320-326.","DOI":"10.1016\/j.beha.2017.09.004"},{"key":"51348","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23):2209-2221.","DOI":"10.1056\/NEJMoa1516192"},{"key":"51349","doi-asserted-by":"crossref","unstructured":"Gerstung M, Papaemmanuil E, Martincorena I. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017; 49(3):332-340.","DOI":"10.1038\/ng.3756"},{"key":"51350","doi-asserted-by":"crossref","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ. Real-world evidence - what is it and what can it tell us?. N Engl J Med. 2016; 375(23):2293-2297.","DOI":"10.1056\/NEJMsb1609216"},{"key":"51351","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"51352","doi-asserted-by":"crossref","unstructured":"Fenwarth L, Thomas X, de Botton S. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021; 137(4):524-532.","DOI":"10.1182\/blood.2020005524"},{"key":"51353","doi-asserted-by":"crossref","unstructured":"Grimwade D, Hills RK, Moorman AV. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-365.","DOI":"10.1182\/blood-2009-11-254441"},{"key":"51354","doi-asserted-by":"crossref","unstructured":"Koreth J, Schlenk R, Kopecky KJ. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22):2349-2361.","DOI":"10.1001\/jama.2009.813"},{"key":"51355","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, van Putten WLJ, Verdonck LF. Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood. 2007; 109(9):3658-3666.","DOI":"10.1182\/blood-2006-06-025627"},{"key":"51356","doi-asserted-by":"crossref","unstructured":"Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018; 93(10):1267-1291.","DOI":"10.1002\/ajh.25214"},{"key":"51357","doi-asserted-by":"crossref","unstructured":"Grimm J, Jentzsch M, Bill M. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv. 2020; 4(16):3864-3874.","DOI":"10.1182\/bloodadvances.2020001904"},{"key":"51358","doi-asserted-by":"crossref","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019; 36:70-87.","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"51359","doi-asserted-by":"crossref","unstructured":"Mawad R, Gooley TA, Sandhu V. Frequency of allogeneic hematopoietic cell transplantation among patients with high-or intermediate-risk acute myeloid leukemia in first complete remission. J Clin Oncol. 2013; 31(31):3883-3888.","DOI":"10.1200\/JCO.2013.50.2567"},{"key":"51360","doi-asserted-by":"crossref","unstructured":"Estey E, de Lima M, Tibes R. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007; 109(4):1395-1400.","DOI":"10.1182\/blood-2006-05-021907"},{"key":"51361","doi-asserted-by":"crossref","unstructured":"\u00d8stg\u00e5rd LSG, Lund JL, N\u00f8rgaard JM. Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia: a national population-based cohort study. Biol Blood Marrow Transplant. 2018; 24(2):314-323.","DOI":"10.1016\/j.bbmt.2017.10.019"},{"key":"51362","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, Reville PK, Kantarjian H. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022; 9(5):e350-e360.","DOI":"10.1016\/S2352-3026(22)00076-X"},{"key":"51363","doi-asserted-by":"crossref","unstructured":"Dholaria B, Savani BN, Hamilton BK. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021; 27(1):6-20.","DOI":"10.1016\/j.bbmt.2020.09.020"},{"key":"51364","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001; 97(11):3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"51365","doi-asserted-by":"crossref","unstructured":"Devillier R, Forcade E, Garnier A. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2022; 6(6):1804-1812.","DOI":"10.1182\/bloodadvances.2021004435"},{"key":"51366","doi-asserted-by":"crossref","unstructured":"Sorror ML, Gooley TA, Storer BE. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. Blood. 2023; 141(3):295-308.","DOI":"10.1182\/blood.2022016916"},{"key":"51367","doi-asserted-by":"crossref","unstructured":"Jentzsch M, Bischof L, Backhaus D. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv. 2022; 6(15):4570-4580.","DOI":"10.1182\/bloodadvances.2022007168"},{"key":"51368","doi-asserted-by":"crossref","unstructured":"Balsat M, Renneville A, Thomas X. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2017; 35(2):185-193.","DOI":"10.1200\/JCO.2016.67.1875"},{"key":"51369","doi-asserted-by":"crossref","unstructured":"Ivey A, Hills RK, Simpson MA. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016; 374(5):422-433.","DOI":"10.1056\/NEJMoa1507471"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282729\/75452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282729\/75943","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11032\/75452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:44Z","timestamp":1794045824000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282729","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}